Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Integrative Skin Science and Research

Neither a doctor nor a teaching hospital

Research payments

$5,183,474

785 payments

Through program year 2025, Integrative Skin Science and Research is reported as receiving $5,183,474 in research payments, across 785 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,297,897 51
2024 Research $1,712,644 93
2023 Research $1,138,279 485
2022 Research $308,085 45
2021 Research $406,764 62
2020 Research $303,385 47
2019 Research $16,420 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,508,207 12 payments
  2. Incyte Corporation $974,386 96 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $845,612 17 payments
  4. E.R. Squibb & Sons, L.L.C. $479,971 13 payments
  5. Dermavant Sciences, Inc. $374,061 484 payments
  6. AbbVie, Inc. $261,808 55 payments
  7. Pfizer Inc. $245,378 30 payments
  8. Arcutis Biotherapeutics, Inc. $238,716 36 payments
  9. Eli Lilly and Company $159,166 2 payments
  10. Boehringer Ingelheim International GmbH $28,909 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $567,197 1 payment
  2. Speso moderate to severe HS Phase IIb/III $527,952 3 payments
  3. ASCEND P3 AD Extension $317,809 2 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting $296,042 5 payments
  5. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $282,894 22 payments
  6. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $245,378 30 payments
  7. A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children With Adults $227,893 298 payments
  8. VOYAGER P3 AD Vaccine Study $190,238 2 payments
  9. OUTPOST Clinical Home Use Study $174,043 2 payments
  10. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $152,606 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record